Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genaera has formed a trodusquemine scientific advisory board with leading experts in the areas of obesity, diabetes and metabolic disorders, to provide guidance on the development of the company's obesity and diabetes treatment trodusquemine.
Subscribe to our email newsletter
Jack Armstrong, president and CEO said: “Genaera is privileged and honored to work with this prestigious group of nationally and internationally recognized experts to guide our trodusquemine (MSI-1436) clinical development. The expertise of this advisory board is a valuable resource to help ensure Genaera adopts the most scientifically focused and clinically effective development plan as we move forward with this unique therapeutic agent.”
Dr Thomas Wadden, professor of Psychology and director of the Center for Weight Loss and Eating Disorders at the University of Pennsylvania, said: “With more than 60 million Americans classified as obese, there is a critical need for innovative therapies to manage metabolic disorders.”
The scientific advisory board (SAB) met to review updated preclinical and new Phase I data on MSI-1436 and provided guidance on the design and conduct of future clinical studies to assure that appropriate safety assessments are addressed and that the trials can maximize detection of the biochemical and/or clinical signals that predict clinical utility.
Additionally, the SAB will address important issues related to the development of a commercially viable agent for the treatment of both obesity and diabetes including emerging changes in the global medical and regulatory environment.